Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:3:37-46.
doi: 10.2147/CEOR.S16655. Epub 2011 Feb 15.

A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy

Giorgio L Colombo  1 , Giovanni B Gaeta, Mauro Viganò, Sergio Di Matteo
Affiliations

A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy

Giorgio L Colombo et al. Clinicoecon Outcomes Res. 2011.

Abstract

Introduction: Chronic hepatitis B (CHB) is a prevalent disease associated with high morbidity, mortality, and impact on health care costs. Antiviral therapy is aimed at reducing hepatitis B virus replication in order to limit progressive liver disease and improve the natural history of the disease. This study estimates the cost-effectiveness of lamivudine, adefovir, telbivudine, entecavir, tenofovir, and pegylated interferon in patients with CHB.

Methods: A Markov model was developed to evaluate the costs and benefits of antivirals in a cohort of patients with CHB (hepatitis B e antigen [HBeAg]-positive and HBeAg-negative) and cirrhosis over a period of 10 years. Different rescue therapies were considered, according to current guidelines. Data on efficacy and changes in quality of life were derived from clinical trials and epidemiological Italian data. Direct costs were assessed from the perspective of the Italian National Health Service.

Results: Tenofovir was associated with lower costs and higher efficacy compared with entecavir, telbivudine, and adefovir, as shown by their incremental cost-effectiveness ratios (ICER) per quality-adjusted life-year (QALY) gained: tenofovir €30,959, entecavir €45,971, telbivudine €62,051, and adefovir €82,824. Even following 1 year of pegylated interferon therapy, tenofovir had a more favourable ICER per QALY gained compared with the other rescue options. The analysis of patients with cirrhosis confirms the results obtained with the CHB cohort though with higher ICERs. Sensitivity analyses on the main variables confirm the results of the base case scenario.

Conclusion: Within the Italian health care system, in patients with CHB, tenofovir is a cost-effective strategy compared with other available therapies. Public health care authorities would benefit from mathematical models designed to estimate the future burden of CHB infection together with the impact of treatment and drug resistance.

Keywords: Markov model; adefovir; chronic hepatitis B; cost-effectiveness; entecavir; lamivudine; pegylated interferon; telbivudine; tenofovir.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structure of the Markov model for chronic hepatitis B.
Figure 2
Figure 2
Total costs at 10 years for drugs and other health costs calculated for a cohort of 100 patients.
Figure 3
Figure 3
Mean cost per patient per year.
Figure 4
Figure 4
Results of one-way sensitivity analyses.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227–242. - PubMed
    1. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359(14):1486–1500. - PubMed
    1. Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2009;18(11):1655–1666. - PubMed
    1. Chang TT, Gish RG, de Man R, et al. BEHoLD AI463022 Study Group A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001–1010. - PubMed
    1. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359(23):2442–2455. - PubMed

LinkOut - more resources